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Responses to injecting drug use have changed focus 
over the last 20 years. Prevalence and incidence of 
human immunodeficiency virus (HIV) among people 
who inject drugs (PWID) in England and Wales were 
examined in relation to these changes. A voluntary 
unlinked-anonymous surveillance study obtained a 
biological sample and questionnaire data from PWID 
through annual surveys since 1990. Prevalence and 
incidence trends were estimated via generalised lin-
ear models, and compared with a policy time-line. 
Overall HIV prevalence among 38,539 participations 
was 1.15%. Prevalence was highest among those who 
started injecting before 1985; throughout the 1990s, 
prevalence fell in this group and was stable among 
those who started injecting later. Prevalence was 
higher in 2005 than 2000 (odds ratio: 3.56 (95% con-
fidence interval (CI) 1.40–9.03) in London, 3.40 (95% 
CI 2.31–5.02) elsewhere). Estimated HIV incidence 
peaked twice, around 1983 and 2005. HIV was an 
important focus of policy concerning PWID from 1984 
until 1998. This focus shifted at a time when drug 
use and risk were changing. The increased incidence 
in 2005 cannot be ascribed to the policy changes, 
but these appeared to be temporally aligned. Policy 
related to PWID should be continually reviewed to 
ensure rapid responses to increased risk.
Introduction 
The vulnerability of people who inject drugs (PWID) 
to blood borne-infection was recognised early in the 
human immunodeficiency virus (HIV) pandemic, with 
the rapid spread resulting in high prevalence among 
PWID in many parts of the world [1-4]. However, a 
number of countries, including the United Kingdom 
(UK), have reported a low HIV prevalence [5-7] among 
PWID, which has been attributed to the timely intro-
duction of comprehensive harm reduction measures, 
including needle and syringe programmes (NSPs) and 
opiate substitution therapy (OST) [8]. In the UK such 
measures were promptly introduced in the mid-1980s 
in response to substantial HIV outbreaks among PWID 
in two Scottish cities [9,10].
In England and Wales, HIV prevalence among PWID 
has been monitored in a consistent way since 1990 
[11,12], and reveals a consistently higher HIV preva-
lence among PWID in London compared to elsewhere 
[11,13]. Throughout the course of the HIV epidemic in 
England and Wales policy related to both injecting drug 
use (IDU) and HIV have changed, as have the patterns 
of drug use (Table 1). This has resulted in changes to 
the extent and types of responses over time: broadly, 
policy related to IDU shifted from a focus on prevent-
ing HIV infection in the late 1980s and early 1990s to a 
focus on criminal justice issues at the end of the 1990s, 
with an increased emphasis on harm reduction from 
2006 onwards (Table 1).
This paper examines trends in HIV prevalence among 
PWID in England and Wales between 1990 and 2011, 
and considers these in the context of the changes in 
policy and responses. 
Methods 
Survey of PWID
In England and Wales PWID have been recruited into 
an annual voluntary unlinked-anonymous survey since 
1990, the methodological details of which have been 
published previously [11]. Briefly, services providing 
harm reduction or addiction treatment interventions to 
people who use drugs throughout England and Wales 
invite clients who have ever injected to participate in 
annual surveys [14]. Those who agree provide an oral 
fluid sample or, since 2009, a dried blood spot (DBS) 
sample and self-complete a brief questionnaire. Agency 
selection reflects the range of services provided to 
PWID as well as reported geographic variations in IDU, 
with the agency selection reviewed regularly.
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Table 1
Timeline of public health responses and policies on HIV and injecting drug use, England and Wales, 1981–2011
Year Event
1981 First AIDS cases diagnosed in the US [59], and first case recognised in the UK [60].
1982 -
1983 HIV (LAV) first isolated [61].
1984 Laboratory test for HIV developed [62]. Preliminary HIV prevalence data [63]. First case of AIDS in PWID in the UK [9].
1985 Sample of PWID in England and Wales suggests ca 2.5% prevalence [64].Laboratory testing for HIV rolled out and HIV (HTLV-III) screening of UK blood donations began [65].
1986
Paper published suggesting HIV prevalence among PWID in Edinburgh and Dundee could be as high as 85% [10].
First clinical trials of anti-retroviral drug (zidovudine) showing benefit [66].
UK’s first NSP opened in Peterborough, Liverpool and London [9].
1987
Pilot study of NSP started with 15 sites across the UK (13 in England) [9].
AIDS Control Act required returns from all local areas including on their provision of preventive services [67].
First description of use of saliva for HIV screening [68].
1988
Advisory Council on the Misuse of Drugs recommended actions to reduce HIV risk behaviours among PWID, later termed the 
Harm reduction approach [27].
Expansion of NSP and OST provision started, continuing into the 1990s [9].
1989 Evaluation of UK NSP pilot published [28].
1990 Sero-behavioural monitoring of HIV in PWID started in England and Wales [14].
1991 -
1992 The new national health strategy Health of the Nation, included a target to reduce needle and syringe sharing [30].
1993
Advisory Council on the Misuse of Drugs second report on HIV among PWID recommended a 'broad based public health 
approach' with targeted interventions such as NSPs and substitute prescribing [69].
National HIV prevalence among PWID (1990–91) between 1 and 2%, but higher in London (ca 4%) [14].
1994 -
1995 Tackling drugs together a strategy for England published, covers many topics and specifically mentions HIV [29].First study published on hepatitis C prevalence among PWID in the UK indicates that this is high [70].
1996 Introduction of HAART [71].
1997 Prevalence of HIV among PWID declined to less than 1% [72].
1998 New UK Drugs Strategy published; focusing on drug-related crime through treating and preventing addiction. Infections among PWID only mentioned briefly [73].
1999
National hepatitis C prevalence among PWID published; this at 35% was much lower than suggested by earlier studies 
[33,34]. Prevalence of HIV among PWID stable [33]. First report on an increase in the level of needle/syringe sharing [33].
Increased crack cocaine use and injection from the end of the 1990s [74]; associated with more frequent injection and 
greater risk [13].
2000
Outbreak of Clostridium novyi infection in PWID. Increase in a range of severe bacterial infections among PWID seen over 
the next few years [25,50].
Welsh Strategy on Drug Use launched (Wales) [75].
2001
National Sexual Health and HIV Strategy launched, focusing on sexual transmission [35].
National Treatment Agency for Substance Misuse (England) established, supported by increased spending on the treatment 
of addiction [76].
2002
Models of Care, a national framework for drug services in England published, little on infections [36].
Drug Strategy updated, infections among PWID still only mentioned briefly [37].
Paper published highlighting sustained increase in needle/syringe sharing [12].
2003 First annual UK report on infections among PWID highlighted concerns about rising levels of infections including HIV [44].
2004 Hepatitis C Action Plan launched (England), with target to reduce transmission among PWID [77].Research among PWID indicated that they see HCV as ‘inevitable’ [53].
2005 Paper published indicating HIV prevalence has been increasing among PWID [11].
2006
Fourth annual report on infections among PWID in the UK, highlighting continuing increase in levels of blood-borne viruses 
[26].
Models of Care updated, greater focus on infections (England) [45].
2007 Drug Related Harm Action Plan, leading to reinvigoration of harm reduction approaches [46].
2008
Harm Reduction Works information campaign launched [48].
A new Drug Strategy launched (England), focusing on reducing crime and drug use, infections among PWID only mentioned 
briefly [47].
2009 NICE Guidance on provision of NSP [49].
2010 A new national Drug Strategy launched, focussing on recovery from addiction, with infections among PWID only mentioned briefly [51].
2011 -
AIDS: acquired immunodeficiency syndrome; HAART: highly active antiretroviral therapy; HCV: hepatitis C virus; HIV: human 
immunodeficiency virus; HTLV: human T-lymphotropic virus type; LAV: lymphadenopathy-associated virus; NICE: National Institute for 
Health and Care Excellence; NSP: needle and syringe programme; OST: opiate substitution therapy; PWID: people who inject drugs; UK: 
United Kingdom; US: United States.
Hyphens (-) indicate no notable events or policy changes for that year.
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Oral fluid specimens have been collected using the 
OraSure device (OraSure Technologies Inc, US) since 
1998; before that the Salivette (Starstedt Ltd, Leicester, 
UK) was used. OraSures were introduced in 1998 to 
optimise the detection of antibodies to hepatitis C 
virus (HCV) [15]. Oral fluid specimens were tested for 
antibodies to HIV (anti-HIV) by an IgG antibody capture 
ELISA (GACELISA) HIV 1+2 (Abbott Murex Diagnostics 
Ltd, UK) and, since production of this kit stopped in 
2004, by an in-house GACELISA with similar perfor-
mance. Reactive specimens underwent further testing 
according to a proven algorithm that included a second 
ELISA and Western blot, for which sensitivity and spec-
ificity approached 100% [16]. 
In 2009, 16% of samples were DBS, rising to 67% in 
2010 and 100% subsequently. For DBS, eluates were 
prepared and screened by the same laboratory using 
the GACELISA HIV 1+2; reactive specimens were subject 
to Western blot analysis to determine the specificity of 
the reaction.
Analysis
Those who had injected drugs in the four weeks before 
participation in the survey where included in the analy-
ses. Trends in HIV prevalence were examined via logis-
tic regression. As previous analysis had indicated a 
higher prevalence and different patterns in London 
compared with elsewhere [11], analyses were per-
formed separately for London and the rest of England 
and Wales. 
Demographics of the population of PWID have changed 
over time [17]; therefore, injecting duration, age and 
sex were controlled for to determine underlying tem-
poral trends. We also aimed to estimate interactions 
between survey year and injecting duration, cor-
responding to a cohort effect for the year injecting 
started. Specifying a model that is flexible enough to 
adequately model changes in prevalence by time and 
injecting duration is difficult due to the small num-
ber of observed cases. Models with individual effects 
for each survey year will fit the data well, but require 
a high number of parameters and do not exploit any 
underlying trends in the data because prevalence in 
each year is assumed to be independent of preceding 
years. We therefore employed polynomial models that 
incorporate quadratic and higher powers of variables 
to fit non-linear trends, similar to Sweeting et al. [18]. 
We used a systematic approach to model selection, with 
models assessed via the Akaike Information Criteria 
(AIC); this statistic balancing model fit with parsimony. 
We focussed on polynomial models, considering poly-
nomials up to degree 5 for time and injecting duration, 
quadratic effects for age and, sex and potential interac-
tions between them. A complete search of all possible 
interactions (which may be the same as or lower than 
the degree of main effects) is not possible as the num-
ber of possible combinations is too large. Therefore we 
undertook a full search of possible interactions (up to 
degree 5) between time and injecting duration effects, 
but only up to degree 2 for their interactions with age 
and sex. Given a large set of candidate models, there 
will inevitably be uncertainty in the model selection 
process. The selected model may not provide the best 
match to the true underlying trend, and subsequent 
inferences do not account for the uncertainty in model 
selection. We therefore calculated model-averaged 
estimates [19] to assess the robustness of the preva-
lence estimates obtained from the selected model. 
Briefly, the method provides a weighted average for 
prevalence estimates, with weights based on the AIC 
score (better scoring models have more influence) 
and accounting for additional between-model vari-
ability in confidence intervals. The idea was that if the 
final model was not dissimilar to the model-averaged 
results, we could be confident that features of the esti-
mated temporal trend were not merely due to a particu-
lar parameterisation.
Incidence
A variety of applications have been used to estimate 
incidence according to age or time from sero-preva-
lence surveys [20]. When surveys are available from 
multiple time points, both age and time effects may 
be estimated. Ades and Nokes define hA(a), a function 
for incidence at age a, and hT(t), a function for time-
specific incidence at time t; and relate them to the pro-
portion susceptible, q(a,t) [21]. Integrating exposure 
between the date of birth, t−a, and the survey date t, 
via the age- and time-specific components, we have:
In the context of HIV in PWID, it is assumed that most 
infections will have occurred via injecting; therefore 
‘age’ in this context corresponds to injecting dura-
tion. Although we refer to the at-risk period as inject-
ing duration is in fact time since first injected, and may 
include periods of cessation; in the absence of infor-
mation on this we assume constant exposure through-
out, averaging over any periods of non-injecting. We 
modelled incidence in a Bayesian framework, replac-
ing the integration above with summation, as data are 
discrete. Point estimates are taken as the median of 
the posterior distributions, with 2.5th and 97.5th per-
centiles forming a 95% credible interval, the Bayesian 
equivalent of a confidence interval. Both the time 
effect, hT(t) and injecting duration effect hA(a) were 
modelled using a random walk function in order to give 
a flexible shape, but capitalise on patterns in the data 
[22]. Due to the low prevalence of HIV and the inherent 
uncertainty of estimating incidence from prevalence, 
incidence of HCV was simultaneously modelled (using 
data from 1998 when anti-HCV testing was introduced 
into the survey), with independent functions for hT(t) 
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but a shared injecting duration effect, hA(a), which had 
the effect of a relative risk for subsequent injecting 
durations following the first year. This increased the 
power to estimate the injecting risk function, based on 
the assumption that risk of infection was proportional 
for all blood-borne infections throughout an injecting 
career, with risky practices corresponding to a general 
increase in risk of infection with both HIV and HCV.
Results 
Between 1990 and 2011, 40,261 specimens were col-
lected in England and Wales from PWID aged 15 to 59 
years who had injected in the previous four weeks. 
Due to missing data on sex (n=198) and/or injecting 
duration (n=1,541), 38,539 were included in the analy-
ses. Of these, 6,892 (17.9%) were recruited in London, 
29,385 (76.3%) were male, 9,156 (23.8%) were younger 
than 25 years (median age: 30 years), and the median 
number time since starting to inject was eight years 
(range: 0–45 years). The overall anti-HIV prevalence 
over the 22-year period was 1.15% (445/38,539). Table 
2 shows the characteristics and HIV prevalence by 
year, injecting duration, age and sex for London and 
rest of England and Wales. HIV prevalence increased 
with age, although this was confounded with injecting 
duration, and was higher in London than elsewhere for 
all subgroups. For both regions, prevalence decreased 
before increasing in the most recent years, although 
patterns were different between London and elsewhere 
(p=0.004).
A number of logistic regression models for HIV preva-
lence had similar AIC scores, but there were consist-
ent features in the highest-scoring models: for the 
rest of England and Wales, most included fourth- or 
fifth-order terms for time (representing fairly complex 
shapes), third-order for injecting duration and second- 
or third- order interactions between them. For London, 
time and injecting duration terms were both up to fifth 
power for most models, and again, with significant 
interactions. As the best scoring models tended to 
differ mainly in the parameterisation of age, sex and 
higher order interactions, which are relatively weak, 
model-averaged results were fairly similar to the best 
scoring model (further details are available from the 
authors on request). Parameter estimates for the final 
models are shown in Table 3.
Table 2
Participant characteristics and HIV prevalence by year, injecting duration, age and sex, London versus the rest of England 
and Wales, 1990–2011 (n=38,539)
London Rest of England and Wales
n Anti-HIV-positive % n Anti-HIV-positive %
Age
15–24 775 11 1.42% 8,381 22 0.26%
25–29 1,490 55 3.69% 8,585 44 0.51%
30–34 1,714 75 4.38% 6,895 33 0.48%
≥35 2,913 129 4.43% 7,786 76 0.98%
Sex
Male 4,948 210 4.24% 24,437 141 0.58%
Female 1,944 60 3.09% 7,210 34 0.47%
Injecting duration (years since first injected)
0–2 961 12 1.25% 6,825 21 0.31%
3-5 975 10 1.03% 6,292 14 0.22%
6–9 1,249 31 2.48% 6,526 25 0.38%
10-15 1,403 78 5.56% 5,961 42 0.70%
>15 2,304 139 6.03% 6,043 73 1.21%
Survey year
1990–95 1,943 92 4.73% 7,374 41 0.56%
1996–99 1,729 36 2.08% 6,857 23 0.34%
2000–03 1,394 56 4.02% 6,039 12 0.20%
2004–07 1,149 49 4.26% 6,000 52 0.87%
2008–11 677 37 5.47% 5,377 47 0.87%
Total 6,892 270 3.92% 31,647 175 0.55%
HIV: human immunodeficiency virus.
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Table 3
Final models for HIV prevalence in London versus the rest of England and Wales, 1990–2011 (n=38,539) 
London Rest of England and Wales
Odds ratio 95% CI p value Odds ratio 95% CI p value
Year
Year 1.57 0.78–3.17 0.207 2.11 1.36–3.26 0.001
Year2 3.59 1.76–7.33 <0.001 3.17 1.64–6.16 0.001
Year3 0.46 0.21–1.01 0.052 0.82 0.68–1.00 0.047
Year4 0.68 0.52–0.88 0.004 0.79 0.64–0.96 0.020
Year5 1.23 1.00–1.50 0.049 - - -
Injecting duration
Inj dur 7.01 2.74–17.95 <0.001 1.36 0.92–2.03 0.126
Inj dur2 0.49 0.19–1.24 0.131 1.76 1.18–2.63 0.006
Inj dur3 0.94 0.46–1.94 0.869 0.83 0.73–0.93 0.001
Inj dur4 1.38 0.86–2.19 0.180 - - -
Inj dur5 0.86 0.76–0.96 0.010 - - -
Age
Age 0.67 0.53–0.85 0.001 1.47 1.03–2.11 0.036
Age2 0.88 0.75–1.04 0.127 - - -
Sex
Female 0.85 0.63–1.15 0.290 1.03 0.70–1.51 0.882
Year × injecting duration
Year ×Inj dur 0.23 0.05–1.11 0.068 0.47 0.34–0.65 <0.001
Year × Inj dur2 2.05 0.69–6.04 0.195 1.15 0.92–1.45 0.220
Year × Inj dur3 1.78 0.62–5.07 0.283 0.99 0.94–1.04 0.787
Year × Inj dur4 0.78 0.49, –1.25 0.300 - - -
Year2 × Inj dur 0.55 0.11–2.76 0.470 1.71 1.23–2.37 0.001
Year2 × Inj dur2 0.16 0.03–0.77 0.023 0.61 0.46–0.80 <0.001
Year2 × Inj dur3 0.48 0.13–1.76 0.268 1.14 1.07–1.22 <0.001
Year2 × Inj dur4 2.38 1.14–4.97 0.021 - - -
Year3 × Inj dur 1.13 0.63–2.02 0.689 - - -
Year3 × Inj dur2 2.00 1.08–3.71 0.027 - - -
Year3 × Inj dur3 1.45 0.85–2.46 0.170 - - -
Year3 × Inj dur4 0.70 0.52–0.94 0.017 - - -
Year4 × Inj dur 0.88 0.55–1.39 0.572 - - -
Year4 × Inj dur2 0.76 0.52–1.12 0.170 - - -
Year4 × Inj dur3 0.86 0.61–1.22 0.406 - - -
Year4 × Inj dur4 1.15 0.95–1.39 0.142 - - -
Other interactions
Year × Age - - - 1.36 1.04–1.79 0.027
Year2 × Age - - - 0.64 0.48–0.85 0.002
Year × Female - - - 0.69 0.48–0.97 0.032
CI: confidence interval; Inj dur: injection duration.
Hyphens (-) denote parameter not included for that region; e.g., Age2 appears in London only.
Odds ratios and 95% CI per standard deviation increase in explanatory variables.
Variables are scaled to have a standard deviation of 1, and powers taken thereof (xy). 
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The interaction between time and injecting duration 
means that the cohorts of PWID that started inject-
ing at different times had different patterns of HIV 
prevalence throughout their injecting careers. Figure 
1 shows observed and modelled HIV prevalence for 
London and elsewhere by 10-year cohorts of the year 
they started injecting. Prevalence in London was gen-
erally stable in those who began injecting before 1980, 
with a peak around 2006, but otherwise there was no 
discernible overall trend over the 22 years, although 
data are sparse. The picture was similar in those who 
began injecting between 1980 and 1989, although 
there was a slight increase over time and again a peak 
in the mid-2000s, tailing off in the last year. Increases 
over time were most dramatic in those who began 
injecting between 1990 and 1999, with a significant 
increase from around 2000. Prevalence in those who 
started to inject from 2000 onwards may also have 
increased around this period, but data are sparse. It 
must be noted that estimates may be unreliable for the 
last one to two years of data, as polynomial functions 
are more sensitive to random variation at the tail ends. 
Model-averaged results were similar for London, but 
with a slightly flatter shape for trends over time, and 
increased standard errors.
In the rest of England and Wales, those who began 
injecting drugs before 1980 experienced a drop in HIV 
prevalence during the 1990s, followed by an increase 
from 2005 onwards. Those who began injecting 
between 1980 and 1999 had relatively low prevalence 
throughout the 1990s, but there was a clear indication 
Figure 1
Observed and modelled HIV prevalence, by cohorts of year started injecting, London (n=6,892) versus the rest of England and 
Wales (n=31,647), 1990–2011.
CI: confidence intervals; HIV: human immunodeficiency virus.
Data points are plotted according to quartiles of sample size. Model predictions are displayed with 95% CI, with estimates based on mean 
covariate levels for that year, hence plotted functions are not entirely smooth. Data were sparse in the pre-1980 cohorts, and some model 
estimates and CI have been omitted due to excessive uncertainty.
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of an increased prevalence from 2000 onwards, fol-
lowed by a possible decline from 2007. The picture 
was similar for the most recent cohort (2000 onwards) 
although again, the possible decline in the last few 
years is not certain. Model-averaged results were near 
identical.
Comparisons of prevalence levels by time and inject-
ing duration were obtained from the model, shown 
in Table 4. Setting 2000 as the baseline year and an 
injecting duration of five years, prevalence was similar 
in 1995 in London (OR: 0.88; 95% CI: 0.39–2.00) and 
elsewhere (OR: 0.71; 95% CI: 0.38–1.33) and increased 
in 2005 in London (OR: 3.56; 95% CI: 1.40–9.03) and 
elsewhere (OR: 3.40; 95% CI: 2.31–5.02) before falling 
again in London in 2010 (OR: 0.59; 95% CI: 0.07–5.02) 
but remaining elevated elsewhere (OR: 4.80; 95% CI: 
2.26–10.21). It needs to be noted that the estimation 
was more uncertain for the recent years.
Incidence
The estimated effect of injecting duration, hA(a), is 
shown in Figure 2. There was a sharp decrease in risk 
after the first year of injecting before the risk rose in 
the fourth year and then declined over time with small 
peaks (e.g. at 10 and 15 years). This shape may be 
partly due to recall bias of age at first injection and the 
limitations of calculating injecting duration from cur-
rent age minus age at first injection.
Trends over time for HIV and HCV are displayed in 
Figure 2. Results show a peak in HIV incidence in the 
mid-1980s followed by a decline, which was seen in 
both regions. The incidence for the rest of England and 
Wales then declined to low levels, while the incidence 
in London continued at a reduced, if fluctuating, rate 
throughout the 1990s. Both regions saw an increase 
from 2000 onwards, with a possible recent decline in 
the rest of England and Wales. Trends in HCV followed 
a similar pattern, but with some notable differences. 
There was a peak in incidence in the 1980s followed by 
a slight decrease and stabilisation in London, and by 
a continuous decline in the rest of England and Wales. 
The incidence then increased in both regions over the 
last 10 years. However, the increase around 2005 in 
the rest of England and Wales was less marked for HCV 
than for HIV.
Discussion 
Our analyses indicate that HIV prevalence among PWID 
in England and Wales has increased since 2000. This 
increase has occurred both in London and elsewhere. 
Prior to 2000, prevalence had been stable and prob-
ably fell in the early 1990s. These variations in prev-
alence would appear to be products of two periods 
of elevated HIV incidence among PWID. The first of 
these was in the early 1980s, before the initial pub-
lic health responses to the HIV epidemic. The second 
peak occurred in the mid-2000s, with increases in new 
HIV infections focused outside London. This second 
increase was preceded by a sharp rise in reported nee-
dle and syringe sharing, which rose from 17% in 1997 
to 33% in 2000, Since then, the level has fallen slowly 
and was 17% in 2011 [23].
Markers of other, more common, infections also serve 
as an indicator of the changing overall exposure 
risks for HIV. HCV prevalence shows a similar pattern 
over time to HIV with the prevalence declining in the 
1990s, followed by a rise since 2000 [17]. Our analysis 
Table 4
Specific comparisons of HIV infection by year and injecting duration, obtained from the final models, London (n=6,892) 
versus the rest of England and Wales (n=31,647), 1990–2011.
Injecting duration
(years)
Survey year
1990
OR (95% CI)
1995
OR (95% CI)
2000
OR (95% CI)
2005
OR (95% CI)
2010
OR (95% CI)
London 
1 NEa 1.36 (0.42–4.45) 0.71 (0.19–2.58) 5.47 (1.83–16.34) 3.24 (0.70–15.05)
3 0.23 (0.00–14.45) 0.69 (0.28–1.67) 0.70 (0.45–1.09) 3.33 (1.29–8.62) 0.79 (0.12–5.25)
5 2.17 (0.27–17.08) 0.88 (0.39–2.00) 1 (ref) 3.56 (1.40–9.03) 0.59 (0.07–5.02)
8 7.40 (1.84–29.85) 2.74 (1.29–5.85) 2.20 (1.49–3.25) 6.03 (2.47–14.73) 1.28 (0.21–7.80)
15 8.39 (1.25–56.53) 16.24 (6.88–38.33) 10.27 (4.07–25.92) 14.78 (6.04–36.15) 20.58 (7.35–57.61)
Rest of England and Wales
1 NEa 0.30 (0.10–0.86) 1.58 (0.91–2.73) 5.53 (2.97–10.31) 2.23 (0.73–6.89)
3 0.07 (0.01–0.57) 0.46 (0.21–1.01) 1.16 (0.92–1.46) 4.10 (2.62–6.41) 3.47 (1.44–8.35)
5 0.35 (0.07–1.82) 0.71 (0.38–1.33) 1 (ref) 3.40 (2.31–5.02) 4.80 (2.26–10.21)
8 2.22 (0.60–8.19) 1.37 (0.81–2.34) 1.01 (0.81–1.26) 3.06 (2.02–4.64) 6.54 (3.26–13.14)
15 28.13 (9.47–83.61) 5.87 (3.14–10.96) 2.03 (1.20–3.46) 4.02 (2.23–7.24) 7.79 (3.89–15.57)
OR: odds ratio; CI: confidence interval.
a NE: Due to lack of data estimates are not reliable.
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Figure 2
Predicted annual incidence rates of HIV and HCV for those injecting drugs for one compared with seven years, London 
(n=6,892) versus the rest of England and Wales (n=31,647), 1990–2011.
HCV: hepatitis C virus; HIV: human immunodeficiency virus 
Blue: HIV; green: HCV.
Bottom panel: relative risk of infection in subsequent years vs first year of injecting. Point estimates and 95% credible intervals.
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indicates that incidences of HCV and HIV have followed 
similar patterns. The transmission of hepatitis B virus 
(HBV) has continued among PWID in 2000s despite 
increased vaccine coverage [24], and bacterial infec-
tions have also been a significant problem [25,26].
There have been many shifts in policy related to blood-
borne viruses (BBVs) among PWID since the middle of 
1980s (Table 1). While it is not possible from a simple 
temporal comparison to establish any direct impact of 
policy changes on HIV prevalence or incidence, there 
do seem to be some temporal alignments. From the 
mid-1980s until well into the 1990s, HIV was a major 
focus of policy in the UK, with national expansion of 
both OST and NSP provision [27-29], and the 1992 
National Health Strategy introduced a target to reduce 
needle/syringe sharing [30]. Estimated incidence of HIV 
declined during the mid-1980s and generally remained 
low, resulting in a decrease in observed HIV prevalence 
in the early 1990s. Reported needle/syringe sharing 
was also stable in the mid-1990s, but the proportion 
of individuals that reported sharing in the preceding 
month then increased from around 1998.
In 1998, there was a shift in policy [31]. Since then 
reducing risks of HIV infection through IDU has not been 
a target. The 1998 UK Drug Strategy focused on reduc-
ing crime and social harms [32] and only peripherally 
mentioned BBVs [30]. This was perhaps not unreason-
able given the low level of HIV and the comparatively 
low HCV prevalence at that time [33,34]. The National 
HIV and Sexual Health Strategy launched in 2001 was 
focused principally on sexual transmission, and IDU 
was only briefly mentioned [35]. Neither was prevent-
ing BBVs prominent in the 2002 National Framework 
for Drug Treatment Services in England [36], nor in the 
Revised Drug Strategy [37].
This policy shift occurred at a time when sharing was 
rising and risky injection practices were becoming 
more common [12,38,39]. It is likely that the overall 
prevalence of IDU was also increasing at this time [40]; 
and there was also a rise in injection frequency due to 
increased crack-cocaine use (usually in combination 
with heroin) [41]. Together these may have resulted in 
a decline in the coverage of NSPs [42]. On the other 
hand, this may have, in part, been mitigated by a fur-
ther expansion in the provision of OST and addiction 
treatment from the early 2000s [43]. However, during 
this period other infections increased among PWID 
[44].
When the National Framework for Drug Treatment 
Services in England was revised in 2006, harm reduc-
tion measures were more prominent [45] and a drug 
related harm action plan, focusing on BBVs and over-
dose, was launched in 2007 [46], although BBV preven-
tion remained peripheral in the updated drug strategy 
of 2008 [47]. However, in 2008 a national harm reduc-
tion awareness campaign was launched [48], six years 
after the increase in needle and syringe sharing was 
reported [12]. These and other recent measures to 
reinvigorate harm reduction [49] may help sustain the 
recent fall in incidence and may lead to a future reduc-
tion in prevalence. Arguably these actions could have 
been implemented sooner, in response to the reported 
increases in sharing [12], hepatitis C prevalence [44], 
and bacterial infections [50,44]. It is unclear whether 
prompt action may have reduced, or even possibly pre-
vented, the rise in HIV infections from 2000 onwards, 
but these findings indicate that policy needs to adapt 
quickly in response to the changing risks in this 
population.
A new drugs strategy was launched in 2010 [51], which 
briefly mentioned BBVs and saw their prevention as 
part of the new emphasis on recovery-focused addic-
tion treatment. Continued monitoring of HIV prevalence 
among PWID through the survey will permit us to assess 
whether the recent drop in incidence is sustained. 
It is important to consider the limitations of our analy-
sis. Firstly, although this study aimed to examine tem-
poral changes in HIV prevalence in detail, analysis 
was constrained by relatively low prevalence. There 
is always a trade-off between fitting a flexible model 
and the danger of over-fitting, and we have tried to 
balance these and assess the robustness of our con-
clusions by using model-averaging techniques. We 
considered a rich array of possible models that could 
capture complexities of the data, using an objective 
function, i.e. AIC, for model selection and weighting. 
Models incorporating cubic splines, which can be fit-
ted to an arbitrarily complex pattern [52], were also 
examined extensively but not found to offer significant 
improvement. 
Estimation of incidence required the joint modelling of 
BBV infection risk by injecting duration, assuming peo-
ple infected with BBVs are likely to exhibit the same 
risky behaviour as HIV- and HCV-infected individuals. 
This may be reasonable where HIV infection in peers 
is unknown, but does not account for the possibil-
ity that PWIDs may behave differently with regard to 
known HIV infections than to known HCV infections, 
with HCV infection perceived by some PWIDs as being 
inevitable [53]. We were also unable to account for sex-
ual transmission of HIV and infection before starting 
to inject, which could potentially alter our conclusions 
regarding timing of infection and the risk attributable 
to injecting. There may also have been some misclas-
sification in relation to the period of exposure, as cur-
rent age minus age at first injection was used to derive 
this. The joint estimation of disease incidence is not 
new; for instance, force of infection for HBV and HCV 
have been estimated jointly via shared frailty models 
[54]. Other studies have demonstrated that there is 
a threshold effect if HCV prevalence is above certain 
levels, indicating a level of risk behaviour that allows 
HIV to spread [55]. This threshold is lower if there is 
heterogeneity in risk [56], and such heterogeneity may 
also influence apparent patterns in risk according to 
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injecting duration [57]. Further investigation of inject-
ing risk patterns and changes over time that makes use 
of data on multiple infections is certainly warranted. 
Finally, it is important to consider the generalisability 
of these findings. The comparative rarity, marginalisa-
tion, and illicit nature of IDU all impede the construction 
of a sampling frame, making the representativeness of 
our sample of PWID impossible to measure. This study 
aimed to minimise sampling biases by using data from 
an established survey that consistently applied the 
same recruitment approach over the 22-year period. 
Studies which have recruited PWID from community 
settings, i.e. not through services, in England and 
Wales have found very few individuals who are not, 
or have not recently been, in contact with the types of 
service used for recruitment here [58]. Even so, caution 
is needed when attempting to generalise these find-
ings to all PWID in England and Wales. 
In conclusion, the incidence and prevalence of HIV 
among PWID in England and Wales have varied mark-
edly over time, with two peaks in estimated incidence. 
While it is not possible to ascribe these changes in 
incidence unequivocally to policy changes, there would 
appear to be a broad temporal alignment. This finding 
suggests that there is a need for particular vigilance 
when changes are made in policy related to PWID. It is 
also important for these policies to be reviewed regu-
larly to ensure a rapid and robust response to signs of 
increased infection risk.
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